Metastatic Colorectal Cancer. Real-World Data Analysis.
The Treatment Choices, Duration and Outcomes in Patients with Ras Wild Type (RAS WT) Metastatic Colorectal Cancer (mCRC). Retrospective, Multi-Center, Real-World Data Analysis
Metastatic Colorectal Cancer
Percentage of use anti-EGFR agents, The anti-EGFR agent selection, throughout of treatment, 3 years|Progression Free Survival (PFS), PFS three years after initiation of treatment with anti-EGFR agents, 3 years treatment
Advers events, Advers event of anti EGFR is defined as any untoward or unfavourable medical occurrence, including any abnormal sign, symptom, or disease, temporally associated with the patient's participation. The CTCAE v.4.0 will use in this research., throughout of treatment, 3 years
Percentage of use biologics in right side tumors., Treatment selection in right side tumors., throughout of treatment, 3 years
In this study, with the given rationale is to reveal treatment approaches, survival data, side effect profile and their management in our country in RAS WT mCRC patients by means of the real-world data collection.